{
  "id": "56cf32e23975bb303a000006",
  "type": "yesno",
  "question": "Can venlafaxine block NET and SERT?",
  "ideal_answer": "Yes, venlafaxine inhibits both the NET and SERT.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/10490914",
    "http://www.ncbi.nlm.nih.gov/pubmed/9252010",
    "http://www.ncbi.nlm.nih.gov/pubmed/12784104",
    "http://www.ncbi.nlm.nih.gov/pubmed/16140280",
    "http://www.ncbi.nlm.nih.gov/pubmed/23090625",
    "http://www.ncbi.nlm.nih.gov/pubmed/15989562",
    "http://www.ncbi.nlm.nih.gov/pubmed/18923402",
    "http://www.ncbi.nlm.nih.gov/pubmed/18418363",
    "http://www.ncbi.nlm.nih.gov/pubmed/18538356",
    "http://www.ncbi.nlm.nih.gov/pubmed/11454918",
    "http://www.ncbi.nlm.nih.gov/pubmed/10884561",
    "http://www.ncbi.nlm.nih.gov/pubmed/11524036",
    "http://www.ncbi.nlm.nih.gov/pubmed/9400006"
  ],
  "snippets": [
    {
      "text": "Treatment for 14 days with 70 mg/kg per day venlafaxine, which inhibits both the NET and SERT, or 10 mg/kg per day phenelzine, a monoamine oxidase inhibitor, produced antidepressant-like effects on behavior without altering NET or SERT expression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18923402",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Paroxetine and venlafaxine are potent serotonin transporter (SERT) antagonists and weaker norepinephrine transporter (NET) antagonists",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18418363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using a novel blood assay that estimates CNS transporter occupancy we estimated the relative SERT and NET occupancy of paroxetine and venlafaxine in human subjects to assess the relative magnitude of SERT and NET inhibition",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18418363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment for 14 days with 70 mg/kg per day venlafaxine, which inhibits both the NET and SERT, or 10 mg/kg per day phenelzine, a monoamine oxidase inhibitor, produced antidepressant-like effects on behavior without altering NET or SERT expression",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18923402",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We then performed the first reported investigation of epistasis between the SERT gene and norepinephrine transporter gene (SLC6A2, alias NET) in AN, as an earlier study suggested that atypical AN responds to the dual serotonin-norepinephrine reuptake inhibitor venlafaxine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12784104",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Of particular interest were the findings that paroxetine, generally thought of as a selective SERT antagonist, possesses moderately high affinity for the NET and that venlafaxine, which has been described as a &quot;dual uptake inhibitor&quot;, possesses weak affinity for the NET",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9400006",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The ratios of measured occupancy ED(50) values (doses at which 50% occupancy occurs) among SERT, NET and DAT sites for duloxetine, venlafaxine, nomifensine, indatraline, DOV 21,947 and DOV 216,303 were consistent with the ratios of the in vitro affinities between these target binding sites",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18538356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090625",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this study in nonhuman primates, we aimed to investigate the relationship between SERT and NET affinity by measuring the in vivo occupancy at both transporters of venlafaxine and milnacipran",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090625",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We hypothesized that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Comparative studies with clinically used antidepressants showed that venlafaxine possessed a profile similar to S33005 but was less potent. Clomipramine likewise interacted with SERTs and NETs but also with several other receptors types, while citalopram and reboxetine were preferential ligands of SERTs and NETs, respectively. In conclusion, S33005 interacts potently with SERTs and, less markedly, with NETs. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11454918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16140280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Taken together, the results from this study indicate that the low dose of venlafaxine blocked selectively the reuptake of 5-HT, whereas the high dose blocked the reuptake of both 5-HT and NE. Moreover, an enhancement of serotonergic neurotransmission by venlafaxine was only achieved under conditions whereby the desensitization of the terminal 5-HT(1B) autoreceptor is appended to that of the somatodendritic 5-HT(1A) receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10884561",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4277061"
  ],
  "exact_answer": "Yes"
}